REZOLVE-AA (rezpegaldesleukin) Phase 2b alopecia areata
Trial setup
- Trial: REZOLVE-AA, Phase 2b, randomized, placebo-controlled. - Population: severe-to-very-severe alopecia areata. - Arms: rezpegaldesleukin 18 µg/kg; rezpegaldesleukin 24 µg/kg; placebo. - Primary endpoint: mean percent reduction from baseline in SALT score at Week 36 (induction period). - Key secondary endpoint (topline): mean percent reduction from baseline in SALT30 score at Week 36.
Model leaderboard
How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better. Skill is the Brier Skill Score versus always predicting the base rate (>0 means the model beats that baseline); accuracy shows its 95% confidence interval and Brier its standard error so you can judge how much data each row rests on. Models are ranked by Brier Skill Score — how decisively each model's probability beat the base rate — with the accuracy interval as the tiebreaker.
No model results yet
This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.